Official Symbol: NPM1provided by HGNC
Official Full Name: nucleophosmin (nucleolar phosphoprotein B23, numatrin)provided by HGNC
Primary Source: HGNC:7910
See related: Ensembl:ENSG00000181163; HPRD:01246; MIM:164040
Gene type: protein coding
RefSeq status: REVIEWED
Organism: Homo sapiens
Lineage: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo
Also known as: B23; NPM; MGC104254; NPM1
Summary: This gene encodes a phosphoprotein which moves between the nucleus and the cytoplasm. The gene product is thought to be involved in several processes including regulation of the ARF/p53 pathway. A number of genes are fusion partners have been characterized, in particular the anaplastic lymphoma kinase gene on chromosome 2. Mutations in this gene are associated with acute myeloid leukemia. More than a dozen pseudogenes of this gene have been identified. Alternative splicing results in multiple transcript variants.

[Top][Help]Genomic regions, transcripts, and products

(plus) Go to reference sequence details Try our new Sequence Viewer

[Top][Help]Genomic context

chromosome: 5; Location: 5q35See NPM1 in MapViewer

[Top][Help]Bibliography

GeneRIFs: Gene References Into Function What's a GeneRIF?

	1.	NPM-ALK kinase has a role in the regulation of responsiveness of tumor cells with cdk dysregulation
	2.	NPM1 exon 12 mutations occur with a considerable percentage in AML patients with normal karyotype, and are associated with higher peripheral white cell count and lower expression of CD34 and CD117.
	3.	Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
	4.	The NPM/ALK alteration affects diverse cellular pathways, and provide novel insights into NPM/ALK-positive anaplastic large cell lymphoma pathobiology.
	5.	study reports on 20 cases with acute myeloid leukemia (AML) with limited differentiation; all of these cases were shown to carry an NPM1 type A mutation
	6.	Acetylated NPM1 transcriptionally regulates genes involved in cell survival and proliferation during carcinogenesis.
	7.	NPM knockdown reduces heat-induced inhibition of DNA DSB repair.
	8.	Folding and unfolding kinetics of the C-terminal domain. This small helical domain folds via a compact denatured state, displaying a malleable residual structure.
	9.	identified novel reciprocal functional interactions between IGF-IR and NPM-ALK
	10.	2 novel NPM1 mutants in de novo AML add new insights into the heterogeneity of genomic insertions at exon 12.
	11.	In (NK) AML patients, complete remission rates and percentage of patients with adequate in vivo blast cell reduction 1 week after the end of the first induction cycle were significantly higher in NPM1(+) patients, but were unaffected by FLT3-ITD status.
	12.	NPM-ALK-induced activation of the PI3-kinase and Jun N-terminal kinase and stress-activated protein kinase proteins, with a role for these in the regulation of p53 activity in an intricate signaling system
	13.	nucleophosmin is a candidate of independent prognostic marker for Ewing's sarcoma patients
	14.	limiting the usefulness of the NPM1 mutation A mutation as a molecular marker in patients with minimal residual disease in acute myeloid leukaemia
	15.	nucleophosmin as a positive post-translational regulator of p21.
	16.	nucleophosmin is consistently cytoplasmic in NPMc(+) AML (because of the presence of NPM1 mutations), whilst it is nucleus-restricted (predictive of a germline NPM1 gene) in blastic plasmacytoid dendritic cell neoplasm
	17.	ATIC associated with nucleophosmin-ALK, and its phosphorylation required ALK activity. ALK-mediated ATIC phosphorylation enhanced its enzymatic activity.
	18.	NPM1 gene mutations are associated with acute myeloid leukemia.
	19.	Association of nucleophosmin with bladder cancer recurrence based on immunohistochemical assessment is reported.
	20.	NPM is essential for cell viability, these data suggest that targeting of NPM by granzyme M may contribute to tumor cell eradication by abolishing NPM function.
	21.	The 2 physiological nuclear export signal motifs mediated NPM1 homo/heterodimerization, influencing subcellular distribution of NPM1wt, mutated NPM1 and p14(ARF) in a 'dose-dependent tug of war' fashion. This event is critical for leukaemogenesis.
	22.	A novel interaction between nucleophosmin (NPM1) and APE1 was characterized.
	23.	Observational study of gene-disease association and genetic testing. (HuGE Navigator)
	24.	NPM1 mutations confer a favorable prognosis in childhood AML and in cytogenetically normal AML in particular.
	25.	Nucleophosmin is a binding partner of nucleostemin in human osteosarcoma cells
	26.	NPM1 expression levels of mRNA and protein in myelodysplastic syndromes were not related to chromosome 5 abnormalities and were almost the same as those in normal bone marrow and acute myeloid leukemia cells
	27.	The ribosomal protein L23 is a negative regulator of Miz1-dependent transactivation.
	28.	detailed cytogenetic analysis of acute myeloid leukaemia with mutated NPM1 in a father and daughter, with different NPM1 mutations
	29.	NPM1 mutants coexisted mainly with FLT3 mutants
	30.	38.9% (14/36) patients with NPM1 mutations simultaneously exhibited internal tandem duplications in the FLT3 gene
	31.	Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	32.	These findings indicate that nucleophosmin is essential for mitotic progression and cell proliferation.
	33.	NPM is an essential protein not only for the formation of normal nucleolar structure, but also for the maintenance of regular nuclear shape in HeLa cells.
	34.	The NPM1-mutated is specific of leukemic cells and shows higher levels at MRD in AML patients presentation.
	35.	Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway through SENP3 and SENP5 proteases.
	36.	Model fits with the hypothesis that acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele.
	37.	structural analysis of nucleophosmin mutations in acute myeloid leukemia
	38.	NPMc(+) acute myeloid leukemia represents a primary event rather than a transformation stage of NPMc(-) acute myeloid leukemia
	39.	NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis.
	40.	SMT3IP1 desumoylates nucleophosmin and might controls its physiological functions at both the nucleolus and other subcellular compartments.
	41.	findings point to DR negativity as another phenotypic feature of AML with NPM1 mutation
	42.	NPM1 mutations were observed in 7 of 51 patients presenting as overt therapy-related acute myeloid leukemia as compared to only 3 of 89 patients presenting as therapy-related myelodysplasia
	43.	The present investigations demonstrate the importance of exposure of the C-terminus of Bax for its interaction with nucleophosmin. These protein-protein interaction assays provide a technical approach for the study of Bax-interacting proteins.
	44.	B23 selectively stores, and protects ribosomal protein S9 in nucleoli and therefore could facilitate ribosome biogenesis.
	45.	p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation
	46.	study confirms in 2562 patients with acute myeloid leukemia the previous observation that NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities
	47.	The leukemia-associated NPMc+ is an in vitro oncogene under the appropriate genetic context
	48.	correlation of PTPN11 mutations with NPM1 mutations and FLT3/ITD among adult AML patients
	49.	NPM1 mutation is a unique genetic event that is specific to Acute myeloid leukemia
	50.	Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB is associated with acute myeloid leukemia carrying NPM1 mutations
	51.	review of mutations of NPM1 associated with AML and the implications for prognosis
	52.	Could regulate androgen receptor (AR) functions by promoting assembly of AR-containing regulatory complexes; high levels might alter AR functions in prostate cancer.
	53.	Fusion protein nucleophosmin (NPM)-ALK activates GTPase Rac1 via phosphatidylkinase 3-kinase (PI3K) and protein-tyrosine kinase c-src (Src) in anaplastic large cell lymphoma patients.
	54.	B23 was found to be associated with the rRNA gene chromatin. Small-interfering-RNA-mediated down-regulation of the B23 expression level resulted in reduction of the transcription rate of the rRNA gene.
	55.	NPM binds to HEXIM1 in vitro and in vivo, and functions as a negative regulator of HEXIM1.
	56.	These results define SENP3 as an essential factor for ribosome biogenesis and suggest that deconjugation of SUMO2 from NPM1 by SENP3 is critically involved in 28S rRNA maturation.
	57.	nucleolar localization determines the stability of ARF but not its primary function
	58.	There was a highly significant trend for worsening in relapse risk (RR) and overall survival (OS) with increasing FLT3/ITD (internal tandem duplication) mutant level.
	59.	a molecular mechanism of B23 in the mitotic inhibition of GCN5-mediated histone acetylation and transactivation.
	60.	c-Jun translocates B23 and ARF from the nucleolus after JNK activation by means of protein interactions
	61.	These results identify a unique miRNA signature associated with Acute myeloid leukemia (AML) carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ AML) and provide evidence that support a role for miRNAs in the regulation of HOX genes.
	62.	NPM1 mutations were not detected in the 28 patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
	63.	AML cells are a major source of Ang-1 in leukemic bone marrow, especially in patients with NPM1 mutations
	64.	mutated NPM peptides can be presented by HLA molecules, suggesting that AML cells carrying cytoplasmic mutated NPM could induce an anti-leukaemic T-cell response
	65.	In this general and unselected AML patient population, NPM1 mutation was not a prognostic indicator of a favorable outcome.
	66.	Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)
	67.	Observational study of gene-disease association. (HuGE Navigator)
	68.	Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
	69.	Observational study of genetic testing. (HuGE Navigator)
	70.	Observational study of genotype prevalence. (HuGE Navigator)
	71.	NPM1 mutations is associated with absence of nucleophosmin leukemic mutants in B and T cells from AML
	72.	Elderly (range 60-85 yr) but medically fit patients with acute myeloid leukemia (AML) carrying NPM1 mutations demonstrate a higher rate of complete remission compared to NPM1 wildtype AML patients.
	73.	B23 distinctively binds Ebp1 isoforms and regulates cell proliferation and survival through p42 and p48, respectively.
	74.	Oncogenic NPM1-ALK contains the NPM1 oligomerization motif plus ALK catalytic domain and mediates malignant cell transformation by epigenetic silencing of signal transducer and activator of transcription STAT5A in T-cell anaplastic large cell lymphomas.
	75.	NPM1 mutations are associated with residual disease of acute myeloid leukemia
	76.	Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia.
	77.	B23 sumoylation regulates its subcellular localization, cell proliferation, and survival activities.
	78.	JunB is a critical target of mTOR and is translationally regulated in NPM-ALK-positive lymphomas.
	79.	This study provides evidence for a novel role for NPM as a negative regulator of CXCR4 signaling induced by CXCL12 that may be relevant to the biology of acute myelogenous leukemia.
	80.	crystal structure of human NPM-core (Met9-Asp122)
	81.	NPM1 mutations were significantly associated with old age, high peripheral white blood cell count, and the subtypes of French-American-British categories M1/M5, but negatively associated with expression of CD34 and CD117 in a Chinese population.
	82.	identify splicing factor as a novel NPM/anaplastic lymphoma kinase-binding protein and substrate
	83.	B23 functions as a chaperone in the viral chromatin assembly process in infected cells.
	84.	NPM1 mutations in acute myeloid leukemia act to achieve maximum nuclear export and cytoplasmic accumulation of NPM1
	85.	mutated NPM1 leads to dysregulated HOX expression via a different mechanism than MLL rearrangement
	86.	In pediatric patients, NPM1 mutations are less common than in adults and tend to affect older patients.
	87.	A new type of NPM mutation was found, and NPM mutations in MDS patients were demonstrated foe the first time. The results provides new hints for NPM gene mutations in the pathogenesis of AML and MDS.
	88.	Frameshift mutations in exon 12 of the nucleophosmin gene (NPM1) result in aberrant cytoplasmic localization of the NPM protein (NPMc(+); NPMc(+) is relatively rare in childhood AML, particularly in younger children
	89.	Nuclear matrix proteins such as mutant Pyst1 and nucleophosmin 1 were downregulated, whereas eIF6 and beta-tubulin were upregulated during cell differentiation in hepatocarcinoma cells.
	90.	Ddetermination of mutations and promoter methylation status of NPM1 using pyrosequencing in 199 samples of myeloid neoplasia including myeloproliferative disorders (MPD).
	91.	NPM1 exon 12 mutations is associated with acute myeloid leukemia
	92.	This study unveils a hitherto unrecognized transcriptional corepressor function of the NPM protein, and highlights a novel mechanism by which NPM regulates cell growth and differentiation.
	93.	Results reveal a molecular mechanism of ARF in regulating ribosome biogenesis and cell proliferation via inhibiting B23.
	94.	Often mutation in acute myeloid leukemia.
	95.	These results provide evidence that phosphorylation at specific sites reduces the affinity of B23 for nucleolar components and might be a factor in regulating its location during the cell cycle.
	96.	nucleophosmin 1 mutations may cause cells to develop along the myelomonocytic lineage
	97.	the functional integrity of the B23 core motif is required for stability, efficient nucleolar localization as well as ARF binding
	98.	Ras and c-Myc play important roles in the up-regulation of nucleophosmin/B23 during proliferation of cells associated with a high degree of malignancy, thus outlining a signaling cascade involving these factors in the cancer cells.
	99.	base sequences are given for NPM1 mutated childhood AML patients; consistent deletion/insertion features are presented
	100.	Review. NPM1 is translocated or mutated in various lymphomas & leukemias, forming fusion proteins or NPM mutant products. The structural, functional, biological, clinical & pathological features of normal & mutant NPM1 & its malignancies are reviewed.
	101.	NPM inhibits ionizing irradiation-induced p53 transactivation, and interacts with p53 in hematopoietic cells.
	102.	Aloe-emodin caused increase in the amount of proform and fragment of nucleophosmin in cytoplasm may be one of the important events for aloe-emodin-induced H460 cell apoptosis pf mpm-small cell lung cancer.
	103.	involvement of NPM/B23 in the acute response of mammalian cells to environmental stress, such as UV rays
	104.	both alterations are crucial for acute myeloid leukemia NPM mutant export from nucleus to cytoplasm; NPM leukemic mutants in turn recruit the wild-type NPM from nucleoli to nucleoplasm and cytoplasm
	105.	unique B23 conformation in hepatoma
	106.	NPM inhibits ARF's p53-dependent activity by targeting it to nucleoli and impairing ARF-Mdm2 association.
	107.	NPM is a crucial regulator of p53
	108.	the NPM1 mutation is not necessarily an early event during leukemogenesis; the NPM1 mutation was a favorable factor for achieving complete remission but was associated with a high relapse rate
	109.	new exon-12 NPM mutations in acute myeloid leukemia
	110.	While complex formation between ARF and NPM retains ARF in the nucleolus and prevents ARF from activating p53, DNA damaging treatments promote a transient subnuclear redistribution of ARF to the nucleoplasm, where promotes p53 activation.
	111.	COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants
	112.	CDK2-BRCA1-NPM pathway coordinately functions in cell growth and tumor progression pathways.
	113.	FRGY2a and YB1 disassemble nucleoli by sequestering B23, which is associated with pre-ribosomes and other structurally important nucleolar components
	114.	A novel mechanism of nucleophosmin (NPM) tumorigenesis establishes NPM as a crucial inhibitor of oncogene-induced apoptosis and senescence.
	115.	Src-kinases, particularly pp60(c-src), associate with and are activated by NPM-ALK expression in various cells, and in cell lines established from patients with large cell lymphoma
	116.	These data suggest that nucleophosmin is an early responder to DNA damage that prevents premature activation of p53.
	117.	results indicate that HCV core can recruit B23 and p300 to relieve the repression effect of YY1 on B23 promoter activity
	118.	identification of Ser-4 in B23 as a major physiological substrate of Polo-like kinase 1
	119.	cleavage of B23 by granzyme b in intact vascular smooth muscle cells is dependent upon both cell type and phenotype
	120.	polyamine depletion increased expression of the NPM gene and enhances NPM nuclear translocation and increased NPM interacts with and stabilizes p53, leading to inhibition of IEC-6 cell proliferation
	121.	marker of proliferation activity of human peripheral lymphocytes
	122.	The molecular signature of cytoplasmic NPM+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that cytoplasmic NPM+ AML may derive from a multipotent hematopoietic progenitor.
	123.	Enforced expression of an NPM cytoplasmic mutant acutely attenuates p53-dependent and -independent functions of Arf tumor suppressor protein, and also affects endogenous NPM localization.
	124.	These findings indicate the involvement of nucleophosmin in the regulation of pre-mRNA processing, and its activity is controlled by CDK2-mediated phosphorylation on Thr(199).
	125.	These results demonstrate a novel mechanism for transcriptional regulation of E2F1 and identify the functional role of nucleophosmin/B23 in modulating the binding of NF-kappaB, E2F1 and pRB to activate E2F1 promoter.
	126.	data indicate that NPM1 exon 12 is mutated in acute myelogenous leukemias but not in other common human cancers, and suggest that the NPM1 mutation may not play a role in the tumorigenesis of common solid cancers
	127.	overexpressed in acute myeloid leukemia while translocations associated with this gene are absent
	128.	BRCA1-BARD1 catalyzes the polyubiquitination of nucleolar phosphoprotein nucleophosmin/B23
	129.	NPM1 mutations represent a common genetic abnormality in adult acute myeloid leukemia and appears to identify patients with improved response toward treatment.
	130.	results suggest that B23 plays an important role in the intracellular localization of the core protein and replication of Japanese encephalitis virus
	131.	The sensitive RQ-PCR assays for NPM1 mutations can now monitor and quantify MRD in AML patients with normal karyotype and NPM1 gene mutations.
	132.	NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells secrete IL-10 and TGF-beta and express FoxP3, indicating their T regulatory (Treg) cell phenotype.
	133.	NPM1 gene mutations cause a frame shift in the C-terminus of exon 12, disrupting the NPM nucleolar-localization signal or generating a leucine-rich nuclear export motif, resulting in abnormal cytoplasmic accumulation of NPM.
	134.	PAI-1 downregulates B23 in LnCAP prostatic cancer.
	135.	These findings suggest that an NPM/MLF1 fusion is the primary molecular abnormality in t(3;5) MDS and AML with multilineage dysplasia, and that cases with NPM/MLF1 may be clinically distinct from other MDS-associated disease
	136.	NPM/ALK-mediated induction of Bcl-XL
	137.	NPM inhibits hypoxia-induced p53 phosphorylation at Ser-15 and interacts with p53 in hypoxic cells; hypoxia-driven cancer progression may require increased expression of NPM to suppress p53 activation and maintain cell survival
	138.	Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.
	139.	overexpression of NPM suppressed PKR activity, enhanced protein synthesis, and inhibited apoptosis. Fanconi anemia lymphoblasts expressed low levels of NPM, which correlated with high ground-state activation of PKR and hypersensitivity to apoptotic cues
	140.	c-Myc-mediated expression of NPM decreases during retinoic acid-induced differentiation of HL-60 cells.
	141.	Nucleophosmin (NPM) may be a Ran-Crm1 substrate that controls centrosome duplication.
	142.	Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
	143.	nucleophosmin is an NF-kappaB co-activator for the induction of the human SOD2 gene
	144.	a novel association of B23 and Gadd45a and implicate B23 as an important regulator in Gadd45a nuclear import.
	145.	NPM1 mutations may be also involved in the pathogenesis of myelodysplastic syndromes.
	146.	constitutive expression of C/EBPbeta in ALK-positive anaplastic large cell lymphoma and its relationship to NPM-ALK
	147.	AUF1 was phosphorylated by ALK in vitro and was hyperphosphorylated in NPM-ALK-expressing cells.
	148.	study could not find any NPM gene mutations in pediatric acute myeloid leukemia with normal karyotype
	149.	Protein B23 is an abundant, multifunctional nucleolar phosphoprotein that behaves like a molecular chaperone, an activity that may be related to its role in ribosome biogenesis

Submit: New GeneRIF Correction

[Top][Help]HIV-1 protein interactions

Protein	Interaction
1. Rev	during nuclear import B23 forms a specific binding complex with Rev which is dissociated by RRE RNA and phosphorylation by casein kinase II (CK2)	PubMed
2.	interaction of B23 with Rev has been implicated in the cytotoxic activity of Rev	PubMed
3.	amino acids 38-52 of Rev have been implicated in the association with B32	PubMed
4.	B23 is associated with the nucleolar localization of Rev	PubMed
5.	B23 stimulates the nuclear import of Rev, an effect that is increased when B23 is phosphorylated by casein kinase II (CK2)	PubMed
6. Tat	The nucleolar shuttle protein B23 binds to HIV-1 Tat and data indicates B23 is necessary for the nucleolar localization of Tat	PubMed

Go to the HIV-1, Human Protein Interaction Database

[Top][Help]Interactions

Description ..........
Product	Interactant	Other Gene	Complex	Source	Pubs
Myc interacts with NPM1 (B23)
NC_000005.8	NP_002458.1	MYC		BIND	PubMed

NP_002511.1	NP_004295.1	ALK		HPRD	PubMed

NP_002511.1	NP_001649.1	ARF1		HPRD	PubMed

NP_002511.1	NP_002750.1	EIF2AK2		HPRD	PubMed

NP_002511.1	NP_001915.1	GADD45A		HPRD	PubMed

NP_002511.1	HAND2	HAND2		HPRD	PubMed

NP_002511.1	NP_003484.1	HIST3H3		HPRD	PubMed
Tat-2 interacts with B23.
NP_002511.1	NP_056842.1	HIV2gp5		BIND	PubMed

NP_002511.1	NP_003945.1	MAP3K14		HPRD	PubMed

NP_002511.1	NP_005372.1	NCL		HPRD	PubMed

NP_002511.1	NP_006161.1	NOP2		HPRD	PubMed

NP_002511.1	NP_005021.2	PLK1		HPRD	PubMed

NP_002511.1	NP_068810.1	RELA		HPRD	PubMed

NP_002511.1	Splicing factor arginine/serine rich 12	SFRS12		HPRD	PubMed

NP_002511.1	Switch associated protein 70	SWAP70		HPRD	PubMed

NP_002511.1	NP_006697.2	TCERG1		HPRD	PubMed

NP_002511.1	NP_000537.2	TP53		HPRD	PubMed
Affinity Capture-Western; Reconstituted Complex
BioGRID:110929	BioGRID:106710	AKT1		BioGRID	PubMed
Affinity Capture-MS; Affinity Capture-Western; Reconstituted Complex
BioGRID:110929	BioGRID:107056	BARD1		BioGRID	PubMed
Affinity Capture-MS; Affinity Capture-Western; Reconstituted Complex
BioGRID:110929	BioGRID:107140	BRCA1		BioGRID	PubMed
Affinity Capture-MS; Reconstituted Complex
BioGRID:110929	BioGRID:123555	CDT1		BioGRID	PubMed
Two-hybrid
BioGRID:110929	BioGRID:114850	HAND2		BioGRID	PubMed
Far Western
BioGRID:110929	BioGRID:113895	HIST3H3		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:120780	LYAR		BioGRID	PubMed
Affinity Capture-Western; Reconstituted Complex
BioGRID:110929	BioGRID:110771	NCL		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:120751	OTUB1		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:116708	RRP1B		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:215383	Rrp1b		BioGRID	PubMed
Co-purification
BioGRID:110929	BioGRID:116707	SWAP70		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:116120	TCERG1		BioGRID	PubMed
Affinity Capture-Western
BioGRID:110929	BioGRID:113164	UBC		BioGRID	PubMed
Affinity Capture-MS
BioGRID:110929	BioGRID:113238	USF2		BioGRID	PubMed
An unspecified isoform of NPM1 (NPM) interacts with XPO1 (CRM1).
	NP_003391.1	XPO1		BIND	PubMed

[Top][Help]General gene information

Markers

RH80894(e-PCR): Links: UniSTS:92753

D16S2968(e-PCR): Links: UniSTS:3283

REN60444(e-PCR): Links: UniSTS:385244

Phenotypes

Leukemia, acute myeloid: MIM: 601626
Leukemia, acute promyelocytic, NPM/RARA type: MIM: 164040

Genotypes

See NPM1 SNP Genotype Report

See NPM1 SNP Geneview Report

Related pseudogene(s)

21 foundReview record(s) in Gene

Homology

Homologs of the NPM1 gene The NPM1 gene is conserved in chimpanzee, dog, mouse, and rat.

Map Viewer (Mouse, Rat)

Pathways

Reactome Event:HIV Infection: REACT_6185

Gene Ontology Provided by GOA

Function	Evidence
NF-kappaB binding	IDA	PubMed
Tat protein binding	IDA	PubMed
histone binding	IDA	PubMed
protein heterodimerization activity	IMP	PubMed
protein homodimerization activity	IDA	PubMed
rRNA binding	IEA
ribosomal large subunit binding	IDA	PubMed
ribosomal small subunit binding	IDA	PubMed
transcription coactivator activity	IDA	PubMed
unfolded protein binding	IDA	PubMed

Process	Evidence
anti-apoptosis	NAS	PubMed
cell aging	IMP	PubMed
cell growth	IEA
cell volume homeostasis	IEA
centrosome cycle	IMP	PubMed
interspecies interaction between organisms	IEA
intracellular protein transport	TAS	PubMed
negative regulation of cell proliferation	IMP	PubMed
negative regulation of centrosome duplication	IMP	PubMed
negative regulation of nuclear mRNA splicing, via spliceosome	IEA
nucleocytoplasmic transport	IDA	PubMed
nucleocytoplasmic transport	TAS	PubMed
nucleosome assembly	IDA	PubMed
positive regulation of NF-kappaB transcription factor activity	IMP	PubMed
positive regulation of cell proliferation	IEA
positive regulation of cellular biosynthetic process	IEA
positive regulation of centrosome duplication	IEA
positive regulation of protein kinase activity	IEA
protein localization	IDA	PubMed
protein oligomerization	IDA	PubMed
rRNA export from nucleus	IEA
regulation of DNA damage response, signal transduction by p53 class mediator	IEA
regulation of cell cycle	IEA
response to stress	IMP	PubMed
ribosomal large subunit biogenesis	IEA
ribosomal large subunit export from nucleus	IEA
ribosomal small subunit biogenesis	IEA
ribosomal small subunit export from nucleus	IEA
ribosome assembly	TAS	PubMed
signal transduction	NAS	PubMed

Component	Evidence
cytoplasm	IDA	PubMed
cytosol	IEA
granular component	IEA
large ribosomal subunit	IEA
nuclear speck	IEA
nucleolus	IDA	PubMed
nucleoplasm	IDA	PubMed
nucleus	IDA	PubMed
ribonucleoprotein complex	IDA	PubMed
small ribosomal subunit	IEA
spindle pole centrosome	IDA	PubMed

[Top][Help]General protein information

Preferred Names: nucleophosmin 1

Names: nucleophosmin 1; numatrin; nucleolar phosphoprotein B23; nucleophosmin/nucleoplasmin family, member 1

[Top][Help]NCBI Reference Sequences (RefSeq)

RefSeqs maintained independently of Annotated Genomes

These reference sequences exist independently of genome builds. Explain

mRNA and Protein(s)

NM_001037738.2 → NP_001032827.1 nucleophosmin 1 isoform 3

Description

Transcript Variant: This variant (3) utilizes an alternate 3'-terminal exon, compared to variant 1, resulting in a shorter protein (isoform 3) with a distinct C-terminus.

Source sequence(s)

AC091980,BC107754

Consensus CDS

CCDS43399.1

UniProtKB/TrEMBL

Q9BYG9

Conserved Domains (1) summary

pfam03066
Location:13 – 116
Blast Score: 374

Nucleoplasmin; Nucleoplasmin
NM_002520.6 → NP_002511.1 nucleophosmin 1 isoform 1

Description

Transcript Variant: This predominant variant (1) represents the longest transcript and encodes the longest isoform (1).

Source sequence(s)

AC091980,BC002398

Consensus CDS

CCDS4376.1

UniProtKB/TrEMBL

A8K3N7

UniProtKB/Swiss-Prot

P06748

Conserved Domains (1) summary

pfam03066
Location:13 – 116
Blast Score: 380

Nucleoplasmin; Nucleoplasmin
NM_199185.3 → NP_954654.1 nucleophosmin 1 isoform 2

Description

Transcript Variant: This variant (2) lacks an alternate in-frame exon, compared to variant 1, resulting in a shorter protein (isoform 2) that lacks an internal segment, compared to isoform 1.

Source sequence(s)

AC091980,AC093246,BC009623

Consensus CDS

CCDS4377.1

UniProtKB/Swiss-Prot

P06748

Conserved Domains (1) summary

pfam03066
Location:13 – 116
Blast Score: 379

Nucleoplasmin; Nucleoplasmin

RefSeqs of Annotated Genomes: Build 37.1

The following sections contain reference sequences that belong to a specific genome build. Explain

Genome Reference Consortium Human Build 37 (GRCh37), Primary_Assembly

Genomic

NC_000005.9

Range

170814797..170837887

Download

GenBank FASTA Sequence Viewer (Graphics)
NT_023133.13

Range

15626070..15649160

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (Celera)

Genomic

AC_000048.1

Range

166847347..166870232

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_922784.1

Range

44475363..44498248

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (HuRef)

Genomic

AC_000137.1

Range

165912916..165935666, complement

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_001838954.2

Range

4526658..4549408, complement

Download

GenBank FASTA Sequence Viewer (Graphics)

[Top][Help]Related Sequences

Nucleotide		Protein
genomic	AC091980.4 (138244..153132)	None
genomic	AC093246.3 (84188..92330)	None
genomic	CH471062.2	EAW61443.1
		EAW61444.1
		EAW61445.1
		EAW61446.1
		EAW61447.1
		EAW61448.1
		EAW61449.1
genomic	U89309.1	AAB94739.1
mRNA	AB042278.1	BAB40600.1
mRNA	AB451236.1	BAG70050.1
mRNA	AB451361.1	BAG70175.1
mRNA	AI687394.1	None
mRNA	AK000472.1	BAA91188.1
mRNA	AK290652.1	BAF83341.1
mRNA	AY347529.1	AAQ24860.1
mRNA	AY740634.1	AAW67752.1
mRNA	AY740635.1	AAW67753.1
mRNA	AY740636.1	AAW67754.1
mRNA	AY740637.1	AAW67755.1
mRNA	AY740638.1	AAW67756.1
mRNA	AY740639.1	AAW67757.1
mRNA	AY740640.1	AAW67758.1
mRNA	BC002398.2	AAH02398.1
mRNA	BC003670.1	AAH03670.2
mRNA	BC008495.1	AAH08495.1
mRNA	BC009623.2	AAH09623.1
mRNA	BC012566.1	AAH12566.1
mRNA	BC014349.1	AAH14349.1
mRNA	BC016716.1	AAH16716.1
mRNA	BC016768.1	AAH16768.1
mRNA	BC016824.1	AAH16824.1
mRNA	BC020467.1	None
mRNA	BC021668.1	AAH21668.1
mRNA	BC021983.1	AAH21983.1
mRNA	BC024716.2	None
mRNA	BC050628.1	AAH50628.1
mRNA	BC107754.1	AAI07755.1
mRNA	BP291033.1	None
mRNA	BT007011.1	AAP35657.1
mRNA	BU661768.1	None
mRNA	CR590741.1	None
mRNA	CR594093.1	None
mRNA	CR595866.1	None
mRNA	CR596514.1	None
mRNA	CR597478.1	None
mRNA	CR601970.1	None
mRNA	CR603012.1	None
mRNA	CR604830.1	None
mRNA	CR605572.1	None
mRNA	CR608915.1	None
mRNA	CR610343.1	None
mRNA	CR612984.1	None
mRNA	CR618462.1	None
mRNA	CR618961.1	None
mRNA	D28343.1	BAA05709.1
mRNA	DQ303464.1	ABC40399.1
mRNA	EF429251.1	ABP97432.1
mRNA	J02590.1	AAA36473.1
mRNA	M23613.1	AAA36380.1
mRNA	M26697.1	AAA36385.1
mRNA	M28699.1	AAA58386.1
mRNA	M31004.1	AAA36474.1
mRNA	X16934.1	CAA34809.1
other-genetic	DQ892032.2	ABM82958.1
other-genetic	DQ895223.2	ABM86149.1

Protein Accession	Links
P06748.2	GenPept	UniProtKB/Swiss-Prot:P06748
Q9BTI9	GenPept	UniProtKB/TrEMBL:Q9BTI9
Q9BYG9	GenPept	UniProtKB/TrEMBL:Q9BYG9
Q9NX34	GenPept	UniProtKB/TrEMBL:Q9NX34